Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Multicenter, open-label study of NPI-0052 in patients with advanced solid tumor malignancies
or refractory lymphoma whose disease had progressed after treatment with standard, approved
therapies that included 2 stages. The initial stage involved dose escalation to an MTD and
determination of a recommended Phase 2 dose. The second stage comprised an expansion cohort
at the recommended Phase 2 dose.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene Triphase Research and Development I Corporation